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ABSTRACT
Nucleotide excision repair in humans involves the co-
ordinated actions of 8- 10 proteins. To understand the
roles of each of these proteins in excision it is
necessary to develop an in vitro excision repair system
reconstituted entirely from purified proteins. Towards
this goal we have expressed in E.coli two of the 8 genes
known to be essential for the excision reaction. XPAC
and ERCC1 were expressed as fusion proteins with the
Escherichia coli maltose binding protein (MBP) and
purified to > 80% homogeneity by affinity chromato-
graphy. The purified proteins either as fusions or after
cleavage from the MBP were able to complement the
CFE of cells with mutations in the corresponding genes
in an excision assay with thymine dimer containing
substrate.
INTRODUCTION
Nucleotide excision repair is the major molecular mechanism for
removing modified bases from DNA. Genetic studies with the
human hereditary disease xeroderma pigmentosum (XP) have
identified 7 genes (XPAC-XPGC) involved in the incision
reaction (1). In addition a number of UV-sensitive rodent cell
lines have been isolated (2) and at least one of these is defective
in a gene, ERCCI, not represented by the XP complementation
groups. Thus, to reconstitute human excision repair in vitro at
least 8 proteins are required (3,4).
An in vitro excision repair system (5,6) is available for
complementation studies between cell-free extract (CFE) from
mutant cell lines (4,5,7) and the system has been used in
complementation assay for purifying repair proteins (8). Since
repair proteins are, as a rule, present in the cell in small quantities,
purifying all of the proteins thought to be required for excision
from their natural source might not be practical. Since most of
these genes have now been cloned, it is reasonable to attempt
to express the proteins in heterologous systems and purify them
with the ultimate goal of reconstituting human excision repair
in vitro. We have initiated such studies using two genes whose
products are thought to be involved in either damage recognition,
XPAC (8,9) or in nuclease function, ERCCI (10). Here, we
describe the expression of these genes in E. coli in soluble form
as fusion proteins with the E. coli maltose binding protein, two
step purification of the proteins, and functional complementation
with the fusion proteins with or without enzymatic digestion to
release the human protein. These results are encouraging
especially in light of recent findings (4) suggesting that native
ERCC1 may not be purified to homogeneity by a functional assay
because it is in a tight complex with ERCC4 in vivo and that




Restriction enzymes were obtained from GIBCO-BRL and New
England Biolabs. Taq DNA polymerase was purchased from
Promega. The expression vector pMAL-c2, amylose resin, and
Factor Xa protease were obtained from New England Biolabs.
Heparin agarose, blue agarose, and DNA cellulose were
purchased from Sigma. Oligonucleotides were synthesized at the
Lineberger Comprehensive Cancer Center (University of North
Carolina) using an Applied Biotechnology Systems DNA
synthesizer. Human cDNA libraries were obtained from
Clontech.
Cloning of XPAC cDNA
Tanaka et al. (11) reported the cloning and sequencing ofXPAC
but the clone has not been made available for general use.
Therefore, we isolated cDNA clones carrying XPAC from
commercial cDNA libraries. The Xgtl 1 and XgtlO (5'-stretch)
HeLa cell cDNA libraries from Clontech Laboratories, Inc. (Palo
Alto, CA) were screened by plaque hybridization. The initial
screening of the Xgtl 1 library was performed with a 32P-labeled
36-mer complementary to bp (679-7 14) of the published XPAC
cDNA sequence (11). After screening about 1.5 x 106 plaques,
one positive clone was identified (pCH 1). Sequencing the insert
by the dideoxy method revealed that the clone contained a 970
bp segment corresponding to bp(674- 1643) ofXPACcDNA and
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597 bp extra DNA (presumably an intron) at the 5' end of the
coding sequence.
Using the insert in pCH 1 as a template, a probe was prepared
by random primer labeling method (12) and used to screen the
XgtlO(5'-stretch) library. Five positive clones were identified
among the 106 plaques screened. One clone (pCH2) was
selected for further analysis. Sequencing revealed that the cDNA
in this clone contained a 1028 bp-insert corresponding to bp
(259- 1286) of XPAC cDNA with 22 bp of unrelated sequence
at the 5' end of the insert. Another probe was prepared by random
primer labeling method using the insert in pCH2 as template,
and the XgtlO(5'-stretch) library was screened again. Of about
2 x 106 plaques screened, four positive clones were identified;
and one of these, pCH3, was selected for further analysis. The
insert in this clone contained bp(33 -726) of XPAC cDNA with
63 bp of unrelated sequence at the 5' end.
A plasmid carrying the entire XPAC cDNA was constructed
by ligating the appropriate restriction fragment from pCH2 and
pCH3 with a synthetic oligomer encoding the 5'terminal 33 bases.
The synthetic oligomer consisted of two complementary
oligonucleotides (a 55-mer and a 57-mer) which were synthesized
to contain bp(l-53) ofXPACcDNA plus 5 additional nucleotides
to generate a SacI site at the 5' end. The two oligomers were
annealed and ligated into pCHA302 which contained the rest of
the gene to generate pCHA801 which carries the entire XPAC
cDNA.
Construction of pMAL-XPAC plasmid
An 857 bp fragment ofpCHA801 carrying the entire XPAC (846
bp) was amplified by PCR. The sense primer was a 21-mer
corresponding to nt(1 -21) of XPAC and the antisense primer
was a 25-mer corresponding to nt(833 -857) (but with a T to
G replacement at position 847 to generate an XbaI site) of the
XPAC cDNA sequence. The PCR product was extracted with
chloroform/isoamyl alcohol (24:1), digested with XbaI, and
ligated with the pMAL-c2 vector that had been digested with
XmnI and XbaI. The resulting plasmid, pMAL-XPAC contains
in-frame fusions of malE-XPAC-lacZa as shown in Figure 1.
Overproduction and purification of MBP-XPAC
E.coli DR153(recA- uvrB-) (13) was found to be optimal
among the several E.coli strains tested as a host for pMAL-
XPAC. Overnight cultures of DR153/pMAL-XPAC were grown
in LB + 100 ug/ml ampicillin. Twenty ml of the overnight culture
were used to inoculate 2 liters of LB containing 0.2% glucose
and 100 jig/ml ampicillin. The cells were grown at 37°C to
A600=0.8 at which time IPTG was added to 0.3 mM and
induction was carried out for 4 hrs. The cells were collected by
centrifugation, rinsed with 40 ml of Rinse Buffer (10 mM
Tris-HCI, pH 7.4, 10 mM NaCl, 1 mM EDTA) and
resuspended in 40 ml of Buffer A (20 mM Tris -HCI, pH 7.4,
200 mM NaCl, 1 mM EDTA, 10 mM 3-mercaptoethanol)
containing 5 ,jtg/ml pepstatin A and 5 zig/ml leupeptin. The cells
were frozen in dry-ice ethanol and stored at - 80°C.
All of the purification steps were carried out at 0-40C and
aliquots of the chromatographic fractions were analyzed by SDS-
PAGE to locate the fusion protein. Frozen cells were thawed
at 40C and sonicated 10x 10 sec with a Branson model W185
sonicator set at maximal output for the small tip. The lysate was
clarified by centrifugation at 9000 x g for 30 min followed by
centrifugation at 100,000xg for 2 hrs. The supernatant was
diluted 1:5 with buffer A and loaded onto a 20 ml amylose column
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Figure 1. Construction of pMAL-XPAC. The 846-bp XPAC cDNA fragment
was generated by XbaI digestion of an 857-bp PCR product of pCHA 801 and
inserted into the pMAL-c2 expression vector that had been digested with XmnI
and XbaI.
equilibrated with the same buffer, at a flow rate of 1 ml/min.
The column was washed with 100 ml of Buffer A and the bound
protein was eluted with Buffer A + 10 mM maltose. Four ml
fractions were collected and analyzed by SDS-PAGE and
Coomassie blue staining.
The fractions containing MBP-XPAC were pooled (16 ml),
diluted 1:2 with Buffer B (25 mM HEPES-KOH, pH 7.6, 1 mM
EDTA, 10 mM ,B-mercaptoethanol, 10% (v/v) glycerol) and
loaded onto an 8 ml heparin agarose column equilibrated with
Buffer B + 0.1 M KCI, at a flow rate of 10 ml/hr. The column
was washed with 56 ml of the same buffer and the bound proteins
were eluted with Buffer B + 1.0 M KCI. Three ml fractions
were collected and analyzed by SDS-PAGE. The fractions
containing the fusion protein were combined (9 ml). One ml of
this was dialyzed against storage buffer (25 mM HEPES-KOH,
pH 7.9, 100 mM KCI, 12 mM MgCl2, 0.5 mM EDTA, 2 mM
DTT, 16.5% (v/v) glycerol), divided into 50 Al aliquots, frozen
in dry ice-ethanol, and stored at - 800C.
To purify XPAC in free form, the remaining 8 ml (1.2 mg)
of the fusion protein was dialyzed against Buffer B + 0.1 M
KCI, treated with Factor Xa at 1: 100 (w/w) ratio of protease
to fusion protein for 12 hrs at 4°C and the extent of cleavage
was monitored by SDS-PAGE. The cleavage reaction mixture
was then loaded onto an 8 ml DNA cellulose column equilibrated
with Buffer B + 0.1 M KCI, at a flow rate of 10 nl/hr. The
column was washed with 5 column volumes of the same buffer,
and XPAC was eluted with Buffer B + 1.0 M KCl. Three ml
fractions were collected, XPAC was located by SDS-PAGE, and
the fractions containing the protein were combined and dialyzed







Xmn and BamH -
digested vector
BamH







f ORI 7.70 Kb
pR ER ac
lauZa




Figure 2. Construction of pMAL-ERCC 1. The plasmid was constructed in two
steps as shown. First, the 3' terminal bp(488- 1048) and then the PCR-amplified
5'-terminal bp(l -487) half was inserted into pMAL-c2.
against storage buffer. The protein was divided into 50 Al aliquots,
frozen in dry ice-ethanol, and stored at - 80°C.
Construction of pMAL-ERCC1 plasmid
The plasmid, pcDE carrying the ERCCI cDNA (14,15) was
kindly provided by Dr J.H.J.Hoeijmakers (Erasmus University,
Rotterdam, The Netherlands). A plasmid for expressing a MBP-
ERCC1 fusion protein was constructed as follows (Fig. 2). A
560 bp fragment corresponding to bp(488 -1048) of the ERCCI
cDNA was excised from pcDE by XmnI and BamHI digestion
and cloned into pMAL-c2 (pMAL-XB560). The bp(l -487) of
the ERCCI cDNA was amplified by PCR and ligated into the
XmnI site of pMAL-XB560 to obtain pMAL-ERCC1.
Overproduction and purification of MBP-ERCC1
The MBP-ERCC1 protein was overproduced, and purified
through the amylose and heparin agarose columns by a procedure
essentially identical to that used for the MBP-XPAC protein,
except that the starting material was a 12-liter culture of
DH5aFlacIq/pMAL-ERCCI induced for 12 hrs with 0.3 mM
IPTG. The peak fractions from the heparin agarose column were
combined (12 ml) and one ml of the combined fraction was
dialyzed against storage buffer. The protein was stored in 50 Al
aliquot at -80°C.
Figure 3. Purification of MBP-XPAC and XPAC. Samples from each of the
purification steps were separated on 10% SDS-PAGE and the gel was stained
with Coomassie blue. Lanes: M, molecular weight markers with the mass given
in kDa; 1, uninduced DR153/pMAL-XPAC cells (250 1d); 2, induced cells (250
1l); 3, cell-free extract (32 jig); 4, amylose column peak fraction (4 Ag); 5, heparin
agarose peak fraction (5 Ag); 6, heparin agarose peak fraction digested with Factor
Xa (4 Ag); 7, DNA cellulose peak fraction (3 jog).
-
figur 4. Purification of MBP-ERCC1I and ERCC1I. The proteins were separated
on a 10% SDS-PAGE and stained with Coomassie blue. Lanes: M, molecular
weight markers; 1, uninduced DH5aFlacIq/pMAL-ERCClI (500 jol); 2, induced
cells (250 jol); 3, cell-free extract (65 Aog); 4, amylose column peak fraction (5
jig); 5, heparin agarose peak fr-action (5 jog); 6, protein from previous step digested
with Factor Xa (5 jog); 7, blue agarose fraction (1 Aog).
The remaining protein was diaylzed against Buffer B + 0.1I
M KCl, treated with Factor Xa at 1:100 (wlw) ratio for 18 hrs
at 40C. The sample was then loaded onto a 12 ml blue agarose
column equilibrated with Buffer B + 0.1 M KCl, at a flow rate
of 10 mi/hr. The column was washed with 60 ml of the same
buffer and then a 50 mfl gradient of 0.1 M to 2.0 M KCl in Buffer
B was applied. Three ml fractions were collected, ERCC 1 was
located by SDS-PAGE and fractions containing the ERCCI1
protein were combined (15 ml) and dialyzed against storage
buffer. The protein was stored in 50 !dl aliquots at - 800C.
Complementation of CFE from XP-A and ERCC1 mutants
with purified proteins
CFE from XP-A lymphoblasts (GM02345B), and CHO-ERCClI
mutants (UV20) (16) were prepared as described previously (17)
and stored at - 80'C until use. The substrate was pUNC 1991-4,
a synthetic plasmid containing four thymine dimers (T < > T)
at predetermined sites and a 32P label at the 11Ith phosphodiester
bond 5' to each thymine dimer (18).
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An in vitro excision assay was employed to test the activity
of purified proteins. This assay measures the release of 27-29
nt-long oligomers from pUNC1991-4 by the human excision
nuclease (18,19,20). Extracts from both XP-A and ERCC1
mutant cell lines are completely defective in this activity (4). The
excision complementation assay was conducted as described
previously (4) with the exception that complementation was done
either by mixing CFE from two mutant cell lines or a mutant
CFE supplemented with the missing protein purified from E. coli.
The reaction mixture (50 yd) contained 40mM HEPES, pH 7.9,
70 mM KCI, 8 mM MgCl2, 2 mM ATP, 20 ytM each dNTPs,
1.2 mM dithiothreitol, 0.3 mM EDTA, 10.2% glycerol, 100 /tg
bovine serum albumin, 50 ,tg phosphoenolpyruvate, 5 units
pyruvate kinase, 366 ng pUC18 as carrier DNA, 200 ng substrate
(- 200,000 cpm), and 100 ,tg ofCFE plus the indicated amounts
of purified proteins in complementation assays. The reaction
mixture was incubated at 30°C for 90 min. Following
deproteinization by treatment with proteinase K and phenol
extraction (5,6), the DNA was precipitated with ethanol,
resuspended in formamide/dye and separated on 10%
polyacrylamide sequencing gels.
RESULTS
Purification of MBP-XPAC and XPAC proteins
The XP-A protein (XPAC) has been purified from calf thymus
(8,2 1), and from E. coli cells expressing the cloned cDNA (22).
Although the natural source is ideal for obtaining the protein,
the scarcity of it in tissues makes it difficult to obtain quantities
sufficient for extensive biochemical and physical characterization.
Similarly, the E. coli expression system of Masutani et al. (22)
yields XPAC in inclusion bodies from which active protein must
be obtained by denaturation/renaturation. As an alternative we
expressed XPAC as a fusion protein with MBP with the aim of
obtaining a soluble protein that can be purified by affinity
chromatography. Figure 3 and Table 1 show that the fusion
protein is greatly overproduced and that much of the
overproduced protein is soluble. As a consequence 1.2 mg of
protein with 90% purity is obtained by a two-column purification
procedure from a 2-liter culture. The majority of the contaminants
are degradation products of the fusion protein or the MBP itself,
because they are not seen with CFE from E. coli without the fusion
protein. After the second column the protein is free of nucleases
(data not shown) or other E. coli proteins.
We considered the possibility that the MBP 'tail' of the fusion
protein may interfere with the interactions of XPAC with other
human proteins which are necessary to bring about the excision
nuclease activity, and thus decided to obtain XPAC protein free
of MBP. The fusion protein contains a Factor Xa cleavage site
at the junction of its two components. Treatment of the protein
with Factor Xa did cleave it to generate MBP and XPAC of the
predicted sizes. However, contrary to our expectation the two
proteins were not in stoichiometric amounts, the ratio of
MBP:XPAC being about 5:1 (Figure 3, lane 6). This is due, in
part, to the degradation of XPAC by Factor Xa and, in part,
to the precipitation of free XPAC. Nevertheless, the remaining
full-length XPAC appears to have native conformation as it binds
specifically to a single-stranded DNA cellulose column and can
be separated from most of the MBP by passing the sample through
this column (Figure 3, lane 7). As it turns out both the free and
the fusion forms of XPAC are functional (see below).
Purification of MBP-ERCC1 and ERCC1 proteins
The ERCC1 protein has not been purified before, either from
its natural source or by expression in a heterologous system. First,
we attempted to express ERCC1 without fusing to another
protein, either from a T5 promoter or a T7 promoter, using the
appropriate E. coli host/vector systems. In the former case the
protein was not overproduced, and in the latter case it was
overproduced but was insoluble. Therefore, we made the MBP-
ERCC1 construct with the aim of obtaining a soluble and
functional protein.
Table 1. Purification of MBP-XPAC and XPAC proteins
Fractions Total MBP-XPAC
volume Protein (XPAC) Yield
nil mg % mg %
1. Cell free extract 200 206.25 2.4 4.95 100
2. Amylose 16 2.22 60.4 1.34 27.1
3. Heparinagarose 9 1.36 90.0 1.22 24.6
4. Factor Xa digestiona (8) (1.21) (16.9) (0.20) (4.1)
5. DNA-cellulose (6) (0.43) (25.8) (0.06) (1.2)
a Only 8 ml of the previous fraction was processed after this step and the yield is expressed relative to this amount.
Table 2. Purification of MBP-ERCC1 and ERCC1 proteins
Fractions Total MBP-ERCC1
volume Protein (ERCC1) Yield
ml mg % mg %
1. Cell free extract 360 894.32 1.0 8.94 100
2. Amylose 12 2.44 50.8 1.24 13.9
3. Heparin agarose 12 1.09 81.8 0.86 9.6
4. Factor Xa digestiona (11) (1.00) (20.3) (0.20) (2.2)
5. Blue Sepharose (15) (0.30) (32.5) (0.10) (1.1)
a Only 11 ml of the previous fraction was processed after this step and the yield is expressed relative to the fraction that was processed.
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Figure 4 and Table 2 show that upon induction of E. coli cells
carrying the pMAL-ERCC 1 plasmid the fusion protein is
overproduced in soluble form, and constitutes 1% of total soluble
cellular proteins. Although a significant fraction of the fusion
protein does not bind to the amylose affinity column for unknown
reasons, sufficient amounts bind such that after the amylose
column the protein is obtained at about 14% yield and 51 %
purity, with the major contaminant being the MBP (Figure 4,
lane 4). The MBP is mostly removed by chromatography on
heparin agarose to yield the MBP-ERCC1 fusion protein at about
82% purity and 10% yield. The major contaminants were
degradation products (as evidence by the facts that control runs
with CFE from strains carrying the pMAL-c2 vector yielded only
the MBP) and thus the protein at this stage of purification was
free of non-specific nucleases or DNA binding proteins from
E.coli. To obtain ERCC1 free of MBP the fusion protein was
cleaved with Factor Xa. Again, ERCC1 was released in
substoichiometric amounts relative to MBP, possibly because of
partial degradation of ERCC1 by Factor Xa. Nevertheless, as
in the case of XPAC, the released ERCC 1 could be purified by
chromatography. The released ERCC 1, in contrast to XPAC,
did not bind to the DNA cellulose column; however, it did bind
to the blue agarose column and was enriched relative to MBP
after chromatography on this resin (Figure 4, lane 7). Thus, we
were able to isolate free ERCC 1, albeit at considerably lower
yields compared to the fusion protein.
Complementation with MBP-XPAC and MBP-ERCC1
The purified XPAC and ERCC1 proteins were tested both as
fusion proteins and as full-length isolates for complementation
of CFE of human XP-A and CHO-ERCCl mutant cell lines.
Fig. SA shows that full complemenation is achieved with 100
ng of MBP-XPAC (lane 4) and substantial complementation is
obtained with 200 ng of MBP-ERCCl (lane 7). These correspond
to about 25-50 nM proteins which are realistic concentrations
for repair proteins. Thus, it appears that the 'MBP tail' of the
fusion proteins does not interfere with the repair proteins
performing their functions. In contrast, the 'free' XPAC and
ERCC1 proteins produced by proteolytic cleavage were less








Figure 5. Complementation of CFE from XP-A and ERCC1 (CHO-complementation group 1 = CHO-CG1) mutants with proteins made in E.coli. 32P-labeled
pUNC 1991-4 (T < > T) was incubated with the indicated CFE and purified protein combinations and analyzed on 10% polyacrylamide sequencing gels. The positions
of the major excision products (27, 28, 29) are indicated. A. Complementation with fusion proteins. M, 30-mer marker ladder; lane 1, XPA-CFE (50 /g) + ERCCI-CFE
(50 Ag); lane 2, XPA-CFE (100 Ag); lanes 3, 4 and 5, XPA-CFE (100 Ag) plus 20 ng, 100 ng, and 200 ng of MBP-XPAC, respectively; lane 6, ERCC1-CFE
(100 jg). The low molecular weight species seen in this lane are generated by non-specific nucleases in the cell-free extract. Lanes 7 and 8, ERCCl-CFE (100
/g) plus 200 ng and 800 ng of MBP-ERCC1, respectively. B. Complementation with XPAC and ERCC1 cleaved from the fusion proteins. M, 30-mer marker
ladder; lanes 1 and 6, XPA-CFE (50 /sg) plus ERCCl-CFE (50 /tg); lane 2, XPA-CFE (100 1Lg); lane 3, XPA-CFE (100 ytg) + XPAC (1 pg); lane 4, ERCC1-CFE
(100 1tg); lane 5, ERCCI-CFE (100 yg) + ERCCI ( 1yg).
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complementation (Figure 5B, lanes 3 and 5). This low specific
activity is partly due to the fact that the 'free' XPAC and ERCC1
preparations contain degradation products and thus only a fraction
of the 1 jig is full length protein. However, even when correction
is made for the degradation products the 'free' XPAC and ERCC1
are still less active than the fusion proteins, presumably because
of lower stability of the non-fusion proteins.
DISCUSSION
Genetic and biochemical data indicate that 8-10 proteins are
involved in carrying out excision repair in humans (see 3,4). The
reconstitution of the human excision nuclease in vitro in a defined
system would require the purification of all of these proteins.
In principle this can be accomplished by purifying all these
proteins from their natural source, by purifying the proteins from
heterologous systems using cloned genes, or by a combination
of both methods. The advantage of the natural source is that the
proteins of interest most likely exist in native form and have
undergone the necessary posttranslational modifications which
are required for certain proteins to attain their functional state.
The main disadvantage of the natural source is that repair
proteins, as a rule, are not abundant proteins and thus extensive
purification is required to obtain sufficient quantities of subunits
for enzymological studies. The advantage of the heterologous
sources is that large quantities can be produced by using the
appropriate host/vector systems, thus making it possible to obtain
pure proteins with few purification steps. The disadvantages are
that human proteins expressed in heterologous systems are often
insoluble, bacteria do not carry out most of the posttranslational
modifications made by human cells, and finally the entire set of
human excision repair genes is not yet available. Thus, both
approaches might be needed to achieve the ultimate goal of
reconstituting excision repair in vitro. Here we have described
the overproduction and purification of two human repair proteins
in E. coli and have shown that these proteins are functional in
a complementation assay.
The XPAC protein has been purified by both methods
mentioned above. Robins et al. (8) and Eker et al. (21) purified
the protein from calf thymus by using either the in vitro repair
synthesis assay (8) or the in vivo unscheduled DNA synthesis
assay following microinjection (21) to follow the protein through
the purification steps. The purified protein was used to show that
XPAC may be the damage recognition subunit of the human
excinuclease. Although some reservation regarding its specificity
for damaged DNA has been expressed (21) the recent
demonstration of high affmity binding to (6-4) photoproducts by
RAD14 which is the yeast homologue of XPAC (9) has
provided additional evidence for the role of XPAC in damage
recognition. In addition to the purification from calf thymus,
XPAC has also been expressed in E. coli by Masutani et al. (22)
in an insoluble form, renatured and shown to be active in an in
vitro repair synthesis complementation assay. The results
presented in this paper show that XPAC can be expressed in
E. coli as a soluble fusion protein with MBP and that the fusion
protein, which can be purified in large quantities appears to be
as functional as the protein from its natural source. Furthermore,
the fusion protein binds tightly to the amylose resin to produce
an XPAC affinity column which can potentially be used to identify
and isolate other proteins which interact with XPAC.
In contrast to the extensive studies that have been carried out
on the XPAC gene and protein, very little is known about the
biochemical properties of the ERCC1 protein even though this
was the first human excision repair gene cloned (14,23) and it
is known to be essential for excision repair (4,24). Sequence
comparison revealed that ERCC1 has significant homology to
the S. cerevisiae excision repair protein RADIO (15). RAD10 is
known to stimulate annealing of complementary DNA strands
(25) and to be in a complex with another excision repair protein,
RADM (26,27), which has a single-strand specific nuclease
activity (10). Although no direct evidence exists as yet for
complex formation between ERCC1 and other excision repair
proteins, in vitro complementation studies by Reardon et al. (4)
have revealed some unexpected complementation patterns
involving ERCC1 which have been interpreted in terms of a
heterodimer formation. It was found that CFE ofERCCJ mutant
was not complemented by CFE from ERCC4 mutant.
Furthermore, CFE from XP-F cell lines was only marginally
complemented by CFE from ERCCJ mutants and was not
complemented at all by CFE of ERCC4 mutants. It was proposed
that ERCC4 and XPFC were identical and that this gene
(XPFC/ERCC4) was the human homolog of RADI and its
product made a complex with ERCC 1. It was further proposed
that the in vitro concentration or conditions of ERCC1 and
ERCC4/XPFC were not conducive for heterodimer formation
(4, see also 28). A corrollary of this conclusion would be that
it would not be possible to complement CFE of either ERCC1
or ERCC4/XPFC mutants with the purified proteins. Therefore,
the complementation we achieved with MBP-ERCC1 was
somewhat surprising.
The most likely explanation for the discrepancy between the
complementation experiments with CFE and with the purified
protein is that the concentrations of ERCC 1 and ERCC4/XPFC
are sufficiently high in vivo to make complex formation possible
but are diluted in the CFE and thus unable to form the
heterodimer. If that is the case, then, by increasing the
concentration of either or both components of the complex it
should be possible to shift the equilibrium towards heterodimer
formation. The results presented in this paper lend strong support
to the proposed model. With 200 ng of ERCC1 protein we
achieved substantial complementation of excision activity of CFE
from the ERCCI mutant cell line. Since in the complementation
assays only 50-100 ,ug of each CFE is used and, since repair
proteins are typically present at a level of about 0-4- i0-5 of
total cellular proteins (see 8), the addition of 200 ng of ERCC1
to 100 ,ag of CFE means increasing the concentration of this
protein 10'-102-fold compared to that which can be
supplemented by CFE from ERCC4 mutants. Apparently such
an increase is sufficient to shift the ERCC 1 + ERCC4 < ---- >
ERCC1I/ERCC4 equilibrium towards the heterodimer form.
In conclusion, in this study we have shown that expression of
human excision repair genes in E.coli as fusion proteins is a
promising approach to isolate the human repair proteins in large
quantities and to eventually reconstitute the entire human exicison
nuclease in a defined system.
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